Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
|
Results for 'Commercial and Pipeline Insight: Hepatitis B' |
|
|
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Vaccines Market Insight Products, Pipelines & Market Outlook |
Jan 2007 | £1,095 | 100% |
| Stakeholder Opinions: Hemophilia The harsh reality of commercialising a great research opportunity? |
Jun 2010 | £2,405 | 99% |
| Commercial Insight: Infectious Diseases Overview | Dec 2007 | £9,615 | 96% |
| Stakeholder Opinions: Hepatocellular cancer | Dec 2010 | £2,405 | 93% |
| Stakeholder Opinions: Biologics in Infectious Diseases Well Defined Target Populations Are Key to Commercial Success |
Mar 2008 | £2,400 | 90% |
| Outlook for RNAi, 2007 siRNA and miRNA in biology, diagnostics and therapeutics |
Jun 2007 | £1,820 | 89% |
| Stakeholder Insight: Non-Hodgkin's Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) | Dec 2009 | £9,615 | 81% |
| Innovations in Combating Infectious Diseases Opportunities in Therapeutics and Diagnostics through Application of Proteomics, Genomics, Nanotechnology, and Novel Sources of Lead Generation |
Jun 2010 | £2,425 | 81% |
| Pipeline Insight: Cancer Overview Gastrointestinal, Skin, Sarcomas |
Jan 2009 | £7,210 | 79% |
| Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
Nov 2006 | £7,210 | 75% |
| Delivering RNAi-Based Therapeutics & Diagnostics Challenges & Opportunities |
Jul 2009 | £945 | 65% |
| New Drug Futures 2009 | Jan 2012 | £1,995 | 63% |
| Biosimilars 2009 - 2014 |
Sep 2009 | £2,940 | 62% |
| Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge Of Turning Technology Into Therapy |
Jul 2007 | £1,999 | 57% |
- Results 1 - 14 of 14
-
-
- 1
-
-
